Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

NuviaRx vs REMEVi

NuviaRx
Graded #69

Level

vs
REMEVi
Graded #70

Level

The verdict

Too close to call — both grade 73.5/100 (C).

NuviaRx and REMEVi land on the same WeighScore, so neither clears the other on our six graded dimensions. NuviaRx sits one line higher on the board (#69 vs #70) on the underlying tiebreak, but it's a genuine coin-flip — pick on the factors and prices that matter most to you below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNuviaRx +30
87
57
Dose & formulationREMEVi +11
72
83
Clinical oversightREMEVi +4
82
86
Labs & monitoringREMEVi +2
53
55
FulfillmentREMEVi +25
72
97
Contract termsREMEVi +14
55
69
NuviaRx · left barREMEVi · right bar

The numbers

MetricNuviaRxREMEVi
WeighScore73.5/10073.5/100
GradeCC
Scorecard rank#69#70
Semaglutide$140/mo (all doses, compounded)$219/mo
Tirzepatide$170/mo (all doses, compounded)$319/mo
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
NuviaRx

Graded #69 · C

Strengths

  • Transparent, affordable pricing — compounded semaglutide from $140/mo, tirzepatide from $170/mo
  • Free delivery included; clinical evaluation and prescription bundled (if eligible)
  • Full legal suite published (Terms, Privacy, HIPAA Notice, Informed Consent, Medical Disclaimer)
  • Named operating entity (NuviaRx Health Inc.) with a US address and phone support

Where it loses points

  • Compounding pharmacy partner not named ('partner pharmacy')
  • Not LegitScript-certified (no certification displayed)
  • Lowest pricing is 'as low as' — likely requires a longer prepaid plan
  • State availability not published
REMEVi

Graded #70 · C

Strengths

  • A genuinely flat rate: 'the same price at every dose', stated as such, with no dose upcharge and no introductory rate to step off
  • Longer terms are published openly rather than used as a teaser — semaglutide falls to $189 on 12 weeks and $149 on 52
  • A daily oral semaglutide tablet is offered alongside the injection
  • Available in all 50 states and DC, with no minimum commitment and no cancellation fee

Where it loses points

  • The flat rate is the highest entry price of the top-scoring programmes here; the cheaper $149 figure needs a full year
  • No FDA-approved brand-name pathway — the Wegovy and Ozempic pages are comparison content, not products
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard